Residual microvascular risk in diabetes: unmet needs and future directions
Paola Fioretto, Paul M. Dodson, Dan Ziegler & Robert S. Rosenson
Published online: 27 October 2009 | doi:10.1038/nrendo.2009.213
The global burden of microvascular disease associated with type 2 diabetes mellitus continues to escalate. Furthermore, conventional standards of care do not completely abolish the risk of diabetic retinopathy, nephropathy or neuropathy in affected individuals. In this Review, the authors highlight the issue of residual microvascular risk and discuss intensive treatment with statins and/or fibrates to target atherogenic dyslipidemia, a potential trigger of the microvascular complications that can develop in patients with type 2 diabetes mellitus.
